China National Medicines Corporation Ltd.
Shanghai Stock ExchangeTotal Valuation
China National Medicines Corporation Ltd. carries a market capitalization of 20.67B, placing it among publicly traded companies globally. Its enterprise value stands at 16.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.67B |
| Enterprise Value | 16.58B |
Share Statistics
China National Medicines Corporation Ltd. currently has 754.50M shares outstanding.
| Shares Outstanding | 754.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
China National Medicines Corporation Ltd. trades at a trailing price-to-earnings ratio of 15.06. The price-to-sales ratio is 0.56, and the price-to-book ratio stands at 1.38.
| PE Ratio | 15.06 |
| PS Ratio | 0.56 |
| PB Ratio | 1.38 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | 466.17 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, China National Medicines Corporation Ltd. trades at an EV/EBITDA multiple of 10.93 and an EV/FCF ratio of 266.97. The EV/Sales ratio of 0.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.93 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.42 |
| EV / EBITDA | 10.93 |
| EV / EBIT | 10.93 |
| EV / FCF | 266.97 |
Financial Position
China National Medicines Corporation Ltd. maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.43, indicating elevated leverage, while an interest coverage ratio of 83.52 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.18 |
| Quick Ratio | 0.54 |
| Debt / Equity | 2.43 |
| Debt / EBITDA | 0.33 |
| Interest Coverage | 83.52 |
Financial Efficiency
China National Medicines Corporation Ltd. posts a return on equity of 9.59 and a return on invested capital of 5.86.
| Return on Equity (ROE) | 9.59 |
| Return on Assets (ROA) | 4.12 |
| Return on Invested Capital (ROIC) | 5.86 |
| Return on Capital Employed (ROCE) | 7.97 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.24 |
Taxes
Over the trailing twelve months, China National Medicines Corporation Ltd. has paid 362.44M in income taxes, reflecting an effective tax rate of 19.14.
| Income Tax | 362.44M |
| Effective Tax Rate | 19.14 |
Stock Price Statistics
China National Medicines Corporation Ltd.'s stock has declined approximately -5.38674% over the past 52 weeks. The 50-day moving average sits at 27.53, while the 200-day moving average is 28.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.38674% |
| 50-Day Moving Average | 27.53 |
| 200-Day Moving Average | 28.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, China National Medicines Corporation Ltd. generated 39.56B in revenue and converted that into 1.47B in net income, yielding earnings per share of 2.03. EBITDA reached 1.52B, while operating income came in at 1.52B.
| Revenue | 39.56B |
| Gross Profit | 2.56B |
| Operating Income | 1.52B |
| Pretax Income | 1.89B |
| Net Income | 1.47B |
| EBITDA | 1.52B |
| EBIT | 1.52B |
| Earnings Per Share (EPS) | 2.03 |
Balance Sheet
China National Medicines Corporation Ltd. holds 7.81B in cash and equivalents against 506.36M in total debt, resulting in a net debt position of -7.61B. Total book value stands at 16.01B, with working capital of 16.96B providing operational flexibility.
| Cash & Cash Equivalents | 7.81B |
| Total Debt | 506.36M |
| Net Debt | -7.61B |
| Equity (Book Value) | 16.01B |
| Book Value Per Share | 21.22 |
| Working Capital | 16.96B |
Cash Flow
After subtracting -47.42M in capital expenditures, free cash flow totaled -47.42M - equivalent to -0.06 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -47.42M |
| Free Cash Flow | -47.42M |
| FCF Per Share | -0.06 |
Margins
China National Medicines Corporation Ltd. operates with a gross margin of 6.47, reflecting its pricing power and cost economics. The operating margin of 3.84 and net profit margin of 3.71 provide insight into operational efficiency.
| Gross Margin | 6.47 |
| Operating Margin | 3.84 |
| Pretax Margin | 4.79 |
| Profit Margin | 3.71 |
| EBITDA Margin | 3.84 |
Dividends & Yields
The company's payout ratio of 38.63 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.82 |
| Dividend Yield | N/A |
| Payout Ratio | 38.63 |
| Shareholder Yield | 5.62 |
| FCF Yield | 0.21 |
Stock Splits
China National Medicines Corporation Ltd.'s most recent stock split took place on June 3, 2009 with a 1:2 split ratio.
| Last Split Date | 6/3/2009 |
| Split Ratio | 1:2 |
Scores
China National Medicines Corporation Ltd. posts an Altman Z-Score of 3.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.29 |